GYRE

GYRE

USD

Gyre Therapeutics Inc. Common Stock

$9.070+0.040 (0.443%)

实时价格

Healthcare
生物技术
美国

价格图表

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$9.030

最高价

$9.225

最低价

$8.860

成交量

0.01M

公司基本面

市值

854.9M

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

0.14M

交易所

NCM

货币

USD

52周价格范围

最低价 $6.11当前价 $9.070最高价 $19

相关新闻

GlobeNewswire

Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that the National Medical

查看更多
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
GlobeNewswire

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today

查看更多
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
GlobeNewswire

Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025 Commercial launch in the PRC of generic nintedanib for the treatment of IPF and avatrombopag maleate tablets for the treatment of

查看更多
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update